Latest Insider Transactions at C4 Therapeutics, Inc. (CCCC)
This section provides a real-time view of insider transactions for C4 Therapeutics, Inc. (CCCC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of C4 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of C4 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,550
-2.44%
|
$33,300
$6.04 P/Share
|
|
Nov 07
2024
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.21%
|
-
|
|
Nov 07
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Nov 07
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Nov 07
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.29%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Kendra Adams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.2%
|
-
|
|
Nov 07
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,102
-1.91%
|
$6,612
$6.04 P/Share
|
|
Nov 07
2024
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+6.11%
|
-
|
|
Oct 28
2024
|
Paige Mahaney Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,800
+50.0%
|
-
|
|
Oct 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,023
+1.7%
|
$10,115
$5.56 P/Share
|
|
Oct 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,474
+7.88%
|
$12,370
$5.56 P/Share
|
|
Sep 18
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,837
-2.2%
|
$11,022
$6.38 P/Share
|
|
Sep 16
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-0.5%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+1.68%
|
-
|
|
Sep 16
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-0.78%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Kendra Adams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+2.6%
|
-
|
|
Sep 16
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,329
-1.53%
|
$19,974
$6.36 P/Share
|
|
Sep 16
2024
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.32%
|
-
|
|
Jul 10
2024
|
Leonard Reyno Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,191
-6.32%
|
$30,955
$5.0 P/Share
|
|
Jul 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,320
+1.98%
|
$9,280
$4.85 P/Share
|
|
Jul 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,836
+9.68%
|
$11,344
$4.85 P/Share
|
|
Apr 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,389
+1.22%
|
$11,112
$8.1 P/Share
|
|
Apr 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,697
+6.7%
|
$13,576
$8.1 P/Share
|
|
Apr 01
2024
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+5.8%
|
$10,864
$8.1 P/Share
|
|
Feb 15
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,560
-3.02%
|
$45,920
$7.9 P/Share
|
|
Feb 14
2024
|
Mark Mossler Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,290
+48.03%
|
-
|
|
Feb 14
2024
|
Kelly Schick Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.32%
|
-
|
|
Feb 14
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.32%
|
-
|
|
Feb 14
2024
|
Leonard Reyno Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,700
+27.25%
|
-
|
|
Feb 14
2024
|
Andrew Hirsch President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
103,400
+32.24%
|
-
|
|
Feb 14
2024
|
Kendra Adams Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,700
+30.91%
|
-
|
|
Feb 14
2024
|
Scott N Boyle Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+34.28%
|
-
|
|
Feb 14
2024
|
Stewart Fisher Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,300
+17.45%
|
-
|
|
Feb 13
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.5%
|
$10,410
$6.53 P/Share
|
|
Feb 13
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.5%
|
$10,410
$6.53 P/Share
|
|
Feb 13
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-2.79%
|
$7,806
$6.53 P/Share
|
|
Feb 13
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-6.48%
|
$10,410
$6.53 P/Share
|
|
Feb 13
2024
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,255
-2.17%
|
$13,530
$6.53 P/Share
|
|
Jan 02
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+8.77%
|
$12,648
$6.52 P/Share
|
|
Jan 02
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,725
+1.53%
|
$10,350
$6.52 P/Share
|
|
Jan 02
2024
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,687
+7.53%
|
$10,122
$6.52 P/Share
|
|
Oct 02
2023
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,089
+28.98%
|
$8,089
$1.7 P/Share
|